Post on 03-Aug-2020
1/25/18©UWMRF 2018 1
Joint Inventors From:
UW-Milwaukee, Medical University of Vienna, TU Wien,
University of Belgrade, and National Taiwan University
Novel α6GABAAR Subtype-Selective Ligands for CNS Disorders and
Trigeminal Pain(OTT1410)
For further information please contact:
Jessica Silvaggi, PhD, CLP
Senior Licensing Manager
1440 East North Ave. Milwaukee, WI 53202
Tel: 414-906-4654
Jessica@uwmrf.org
Current Problems with CNS Drugs
• Many GABAergic drugs on the market today offer little selectivity towards various subtypes of GABAA receptors, and thus exhibit undesired side effects
• These include sedation, ataxia, amnesia, tolerance, and addiction
• There has been a lack of new drugs developed for CNS disorders, while the social, clinical, and economic needs are growing
1/25/18©UWMRF 2018 2
Our Solution: Novel α6GABAAR ligands
Recently, the α6 subunit-containing GABAA receptor (α6GABAAR) has been implicated in neuropsychiatric disorders with sensorimotor gating deficits, migraine, orofacial pain and depression.
• α6GABAAR-selective positive allosteric modulators (α6GABAAR PAMs)
– First-in-Class: First ligands highly selective to α6GABAARs
– Functionally Selective: silent at α1- and α5-GABAARs
• Devoid of sedative, motor-impairing, amnesia side effect
• Should be no tolerance and non-addictive
– Effective: Promising results in animal models for several indications
– Pharmacokinetic profiles: Lead compounds show
• Good metabolic stability (in vitro)
• Excellent bioavailability (oral)
• Appropriate brain concentrations (oral)
– Safe: Lead compounds show a lack of liver or kidney toxicity
1/25/18©UWMRF 2018 3
• PCT/US2016/035761 nationalized Fall/Winter 2017
• U.S. Utility Patent Pending
• EP Patent Pending
Looking for a development partner to:
• Provide support for follow up animal testing in lead compounds
• Aid in moving towards the regulatory approval process and IND filing
• License the technology for development of new drugs
1/25/18©UWMRF 2018 4
Intellectual Property and Licensing
Market Potential
Potential Applications
• Neuropsychiatric disorders with sensorimotor gating deficits
– Schizophrenia
– Tic disorders (Tourette’s syndrome), Obsessive compulsive disorder, Attention deficit disorders
– Panic disorder, Nocturnal enuresis, Antisocial personality disorder, Mania, Premenstrual dysphoric disorder, Huntington’s disease
• Depression
• Trigeminal pain: Migraine, Trigeminal orofacial pain
Market
• 45% of people will be affected by some type of neuropsychiatric disorder
• Global migraine sales are expected to grow to $8.7 billion by 2026, however current treatments leave a large number of patients undertreated
• The global temporomandibular joint (TMJ) disorders market is expected to reach $1.2B by 2023, while the CNS therapeutic market is expected to reach $128.9 billion by 2025
• Response rate to off-label use of drugs in post-traumatic trigeminal neuropathy is around 11%; the need is urgent for more efficient and tolerable drugs
1/25/18©UWMRF 2018 5
GABAA Receptors: Established Drug Targets
1/25/18©UWMRF 2018 6
• Chloride ion channel
• Well characterized CNS activity
• Positive modulators work at allosteric sites and increase channel efficacy
• Receptor is readily druggable; approved small molecule drugs in wide-spread clinical use
• α6GABAAR have been found to be located in the cerebellum and trigeminal ganglia
• Compounds targeting α6GABAARs can rescue a disrupted pre-pulse inhibition (PPI), which is a common endophenotype manifestation present in many neuropsychiatric disorders
The GABAA Receptor (GABAAR) α6β3γ2
1/25/18©UWMRF 2018 7
• The GABAAR α6β3γ2 subtype is a pentameric ligand-gated chloride channel comprised of two α6, two β3 and one γ2 subunit
• Pyrazoloquinolinones mediate their effects at the α6+β3- interface (PQ Site) as positive allosteric modulators and act at the diazepam insensitive benzodiazepine (DI-Bz) site (α6+γ2-interface) as null modulators
• The PQ site, the DI binding site and the endogenous ligand (GABA) binding sites at the β3+α6- interfaces are displayed
Image modified from Jacob et al., Nature Reviews Neuroscience, 2008.
GABAAR α6β3γ2 subtype selectivity
1/25/18©UWMRF 2018 8 8
9
Deuterated and N-Hetero analogs retained activity at the α6GABAAR
1/25/18©UWMRF 2018
Analogs retain activity at the α6GABAAR
10
Ligand
Metabolic Stability Pharmacokinetics
t1/2
HLM (h)
t1/2
MLM (h)
CMAX
Plasma (ng / mL)
t1/2
Plasma (h)
CMAX
Brain (ng / g)
t1/2
Brain (h)
PZ-II-029 3.6 ± 0.6 3.2 ± 0.1 5050 ± 770 1.51 ± 0.04 352 ± 17 1.96 ± 0.37
DK-I-56-1 8.7 ± 0.6 10.5 ± 0.9 4430 ± 320 3.54 ± 0.71 589 ± 93 2.28 ± 0.32
RV-I-029 11.1 ± 3.6 14.3 ± 2.8 3740 ± 390 2.46 ± 0.15 657 ± 71 2.60 ± 0.27
DK-I-60-3 13.0 ± 2.9 14.1 ± 3.3 3410 ± 250 2.64 ± 0.54 534 ± 14 3.52 ± 0.71
DK-I-86-1 12.5 ± 3.1 9.2 ± 0.9 1250 ± 80 17.99 ± 15.48 215 ± 23 9.07 ± 5.45
Improvement of Metabolic Stability
• OCD3 and N-hetero Substitution Improved Metabolic Stability and Pharmacokinetic Profile• Deuteration of A or D-ring methoxy group increased the metabolic stability• N-Hetero introduction into D-ring also increased the metabolic stability• Only deuterated compounds exhibited enhanced bioavailability (Cmax, Brain)
1/25/18©UWMRF 2018
Pre-pulse inhibition of the Startle response (PPI)
Geyer et al., Mol Psychiatry. (2002) 7:1039
PPI: A weaker pre-stimulus (pre-pulse) inhibits the reaction (startle response) of an organism to a subsequent strong startling stimulus (pulse), a measurement of sensorimotor gating function
1/25/18©UWMRF 2018 11
• Mouse model mimicking schizophrenia based on the hyper-dopaminergic hypothesis
• Methamphetamine (METH), a hyperdopaminergic agent, significantly disrupted PPI induced by two protocols (71-115 dB and 77-115 dB) in mice
• All α6GABAAR PAMs (10 mg/kg) effectively rescued the METH disruption of PPI
1/25/18©UWMRF 2018 12
0
20
40
60
80
71-115 dB
METH 2 mg/Kg
77-115 dB
METH 2 mg/Kg
Vehic
le
Vehic
le
Vehic
le
Vehic
le
***
##
#
##
##
###
DK
-I-5
6-1
DK
-I-5
6-1
DK
-I-5
6-1
DK
-I-5
6-1
DK
-I-5
9-1
DK
-I-5
9-1
DK
-I-5
9-1
DK
-I-5
9-1
DK
-I-5
8-1
***
#
DK
-I-5
8-1
DK
-I-5
8-1
DK
-I-5
8-1
PP
I (%
)
0
20
40
60
8071-115 dB 77-115 dB
Vehic
leC
om
pound 6
LA
U 1
59
LA
U 4
63
I-29
Vehic
leC
om
pound 6
LA
U 1
59
LA
U 4
63
I-29
Vehic
leC
om
pound 6
LA
U 1
59
LA
U 4
63
I-29
Vehic
leC
om
pound 6
LA
U 1
59
LA
U 4
63
I-29
METH 2 mg/Kg METH 2 mg/Kg
*** ***
###
#
#####
###
###
###
###
PP
I (%
)α6GABAAR PAMs rescued the PPI impairment
0
20
40
60
80
Methamphetamine 2 mg/Kg
Methamphetamine 2 mg/Kg
77-115 dB 77-115 dB
Vehicle Vehicle
Furo Furo Furo Furo Furo Furo
C6 C11 C6 C11
***
******
**
**
**
**
*** ***
***###
######
###
&& &&&
&&
&&&
Pre
pu
lse i
nh
ibit
ion
(%
)
• Two α6GABAAR PAMs (C6 and C11) significantly rescued METH-induced PPI disruptions
• Furosemide, an α6GABAAR-selective antagonist, blocked their effects, confirming α6GABAAR as the action target
The furosemide-sensitive effects of α6GABAAR PAMs
1/25/18©UWMRF 2018 13
Reduction of Trigeminal Neuropathic Pain
1/25/18©UWMRF 2018 14
(A) Injections of 10mg/kg DK-I-56-1 or placebo (days 1 to 14) to rats subjected to ligature of the infraorbital nerve or sham surgery, with(B) respective scores of reactivity to von Frey filaments(C) Injections of 10mg/kg DK-I-56-1, 10mg/kg DK-I-87-1 or placebo (days 15 to 28) to rats with the already existing trigeminal neuropathy, with(D) respective scores of reactivity to von Frey filaments
Two-week repeated treatment with DK-I-56-1 in a rat model of trigeminal neuropathycan provide both, a preventive and a therapeutic effect on neuropathic pain
• Capsaicin-induced migraine model; topiramate (TPM) is a clinically effective anti-migraine agent, and was used as a positive control
• Compound 6 significantly decreased the number of c-Fos-ir neurons in the TCC and CGRP-ir in TG induced by capsaicin
• Compound 6 reversed capsaicin-induced depletion of dural CGRP-ir
• Suggests potential for migraine treatment
1/25/18©UWMRF 2018 15
Trigemino-cervical complex (TCC) Trigeminal ganglia (TG) Dura mater
Cpd 6 Performs Similar to Clinical Migraine Agent
Toxicity and Drug Potential Assays
16
• GABAAR binding >1000 fold higher than all “off target” receptors (46) tested
• Ligands are non-toxic to kidney and liver cells even at 400 µM
• Studies of locomotion on the rotarod confirmed that ligands are not sedating or ataxic in models Rotarod Device
Ligand BZP Rat Brain Site Binding Affinity (nM)
Radioligand % Inhibition Cytotoxicity
BZP Rat Brain Site
hERG Channel
HEK293 (Kidney) LD50 (µM)
HEPG2 (Liver) LD50 (µM)
PZ-II-029 2.7 92.4 7.4 NA NA
DK-I-56-1 2.1 96.2 0.1 >400 >400
RV-I-029 2.0 96.7 6.9 >400 >200
DK-I-60-3 2.3 94.5 8.7 >400 >400
DK-I-86-1 21.7 98.2 8.6 >400 >400
1/25/18©UWMRF 2018
Next Steps
• ~$700,000 in funding needed to conduct further experiments on animal models mimicking Tourette syndrome, trigeminal pain, depression, and tinnitus.
• In need of collaborations to conduct drug development in preclinical studies in the safety pharmacology, toxicology assessments, and pharmacokinetic studies
1/25/18©UWMRF 2018 17
Acknowledgements and Collaborations
Daniel Knutson & Revathi KodaliNicholas Zahn & Alec Huber
Michael Rajesh StephenRanjit Verma, Christopher Witzigmann & Matheus Meirelles
Alexander Arnold & James Cook
18
Brian Roth
Pi-Chuan Fan
Lih-Chu ChiouMarco Treven & Zdravko Varagic
Margot Ernst & Werner SieghartBranka Divovic & Vladimir Dobricic
Miroslav Savic
Acknowledgements and Collaborations
Laurin Wimmer & David Siebert
Marko D. Mihovilovic
1/25/18©UWMRF 2018